The Impact of FLT3 Inhibitors for the Treatment of AML

Video

Meir Wetzler, MD, from Roswell Park Cancer Institute, discusses the potential impact of FLT3 inhibitors for the treatment of patients with acute myeloid leukemia.

Clinical Pearls

Meir Wetzler, MD, chief, Leukemia Section, Department of Medicine, Professor of Medicine, Department of Medicine, Roswell Park Cancer Institute, discusses the potential impact of FLT3 inhibitors for the treatment of patients with acute myeloid leukemia.

  • In CML, initially only imatinib was available in the frontline, but now nilotinib and dasatinib are approved.
  • FLT3 inhibitors did not show significant efficacy in the relapsed/refractory setting of AML, so they were evaluated in the frontline.
Recent Videos
Mazyar Shadman, MD, MPH, an expert on CLL
Mazyar Shadman, MD, MPH, an expert on CLL
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Mazyar Shadman, MD, MPH, an expert on CLL
Related Content
ctDNA Monitoring in Breast Cancer Treatment: Early Signs and Future Directions

ctDNA Monitoring in Breast Cancer Treatment: Early Signs and Future Directions

Sabrina Serani
July 26th 2024
Article

Mridula George, MD, discussed a study investigating ctDNA monitoring during neoadjuvant therapy of breast cancer.

Read More

Understanding the Role of Zanubrutinib for the Treatment of CLL

Understanding the Role of Zanubrutinib for the Treatment of CLL

Rohit Gosain, MD;Rahul Gosain, MD
April 23rd 2024
Podcast

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Listen

Desai and Participants Differentiate BPDCN From Other Diagnoses

Desai and Participants Differentiate BPDCN From Other Diagnoses

Targeted Oncology Staff
July 25th 2024
Article

During a Case-Based Roundtable® event, Pinkal Desai, MD, MPH, discusses the presentation of blastic plasmacytoid dendritic cell neoplasm vs other diseases in a patient case.

Read More

Exciting Activity in Chronic Lymphocytic Leukemia

Exciting Activity in Chronic Lymphocytic Leukemia

Nichole Tucker;Cyrus M. Khan, MD
May 31st 2023
Podcast

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Listen

Immunotherapy for Angiosarcoma: Promising Results for Scalp and Face Tumors

Immunotherapy for Angiosarcoma: Promising Results for Scalp and Face Tumors

Sabrina Serani
July 20th 2024
Article

Juneko Grilley-Olson, MD, discussed findings from a phase 2 study investigating the addition of immunotherapy to chemotherapy for the treatment of advanced angiosarcoma.

Read More

Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC

Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC

Jordyn Sava
July 17th 2024
Article

Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.

Read More